Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
Study Identifier:
ALXN1840-WD-205
ClinicalTrials.gov Identifier:
EudraCT Identifier:
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Available Documents
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Bis-Choline Tetrathiomolybdate
Date
Dec 2020 - May 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
- Diagnosis of WD by Leipzig Criteria ≥ 4 or by historical test results.
- Continuous treatment for WD with penicillamine, trientine or zinc for at least 1 year prior to screening.
- Body mass index \< 30 kilograms/meter squared.
- Able to cooperate with a percutaneous liver biopsy.
- Willing and able to follow protocol-specified contraception requirements.
- Capable of giving signed informed consent.
Exclusion Criteria
- Decompensated cirrhosis or Model for End Stage Liver Disease score \> 13.
- Modified Nazer score \> 7.
- Clinically significant gastrointestinal bleed within past 3 months.
- Alanine aminotransferase \> 2 × upper limit of normal.
- History of bleeding abnormality or known coagulopathy, including platelet count \< 100,000, and international normalized ratio for prothrombin time ≥ 1.5.
- Participant unwilling to accept blood products, if required.
- Marked neurological disease requiring either nasogastric feeding tube or intensive inpatient medical care.
- Hemoglobin less than lower limit of the reference range for age and sex.
- Participants in renal failure, defined as in end-stage renal disease on dialysis (chronic kidney disease 5) or creatinine clearance \< 30 milliliters/minute.
- Lymphoma, leukemia, or any malignancy within the past 5 years.
- Current or chronic history of liver disease not associated with WD.
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Bis-Choline Tetrathiomolybdate
Date
Dec 2020 - May 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
- Diagnosis of WD by Leipzig Criteria ≥ 4 or by historical test results.
- Continuous treatment for WD with penicillamine, trientine or zinc for at least 1 year prior to screening.
- Body mass index \< 30 kilograms/meter squared.
- Able to cooperate with a percutaneous liver biopsy.
- Willing and able to follow protocol-specified contraception requirements.
- Capable of giving signed informed consent.
Exclusion Criteria
- Decompensated cirrhosis or Model for End Stage Liver Disease score \> 13.
- Modified Nazer score \> 7.
- Clinically significant gastrointestinal bleed within past 3 months.
- Alanine aminotransferase \> 2 × upper limit of normal.
- History of bleeding abnormality or known coagulopathy, including platelet count \< 100,000, and international normalized ratio for prothrombin time ≥ 1.5.
- Participant unwilling to accept blood products, if required.
- Marked neurological disease requiring either nasogastric feeding tube or intensive inpatient medical care.
- Hemoglobin less than lower limit of the reference range for age and sex.
- Participants in renal failure, defined as in end-stage renal disease on dialysis (chronic kidney disease 5) or creatinine clearance \< 30 milliliters/minute.
- Lymphoma, leukemia, or any malignancy within the past 5 years.
- Current or chronic history of liver disease not associated with WD.
Protocol Summary
The main objective of the study is to evaluate the change in liver copper (Cu) concentration following 48 weeks of treatment with ALXN1840 in adult participants with Wilson Disease (WD) who have been previously treated for at least 1 year with standard of care (that is, trientine, penicillamine, or zinc). In the Treatment Period, efficacy and safety of ALXN1840 will be assessed at Week 48.
Trial Locations
Location
Status
Location
Research Site
Sacramento, California, United States, 95817
Status
N/A
Location
Research Site
Ann Arbor, Michigan, United States, 48109
Status
N/A
Location
Research Site
Dallas, Texas, United States, 75235
Status
N/A
Location
Research Site
Toronto, Ontario, Canada, M5G 2C4
Status
N/A
Location
Research Site
Århus N, Denmark, 8200
Status
N/A
Location
Research Site
Grafton, New Zealand, 1010
Status
N/A
Go to page